Does the media favor CNTA or INSM?

In the previous week, Insmed had 12 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 16 mentions for Insmed and 4 mentions for Centessa Pharmaceuticals. Insmed's average media sentiment score of 1.52 beat Centessa Pharmaceuticals' score of 1.33 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 14 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer BNTX or CNTA?

In the previous week, BioNTech had 6 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 10 mentions for BioNTech and 4 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat BioNTech's score of 0.59 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Centessa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CNTA or ROIV?

In the previous week, Roivant Sciences had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 6 mentions for Roivant Sciences and 4 mentions for Centessa Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.42 beat Centessa Pharmaceuticals' score of 1.33 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CNTA or MRNA?

In the previous week, Moderna had 24 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 28 mentions for Moderna and 4 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat Moderna's score of 0.46 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 10 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Neutral

Centessa Pharmaceuticals (CNTA) Competitors

$39.85 -0.05 (-0.13%)

Closing price 04:00 PM Eastern

Extended Trading

$39.84 -0.02 (-0.04%)

As of 04:10 PM Eastern

Compare

CNTA vs. INSM, BNTX, ROIV, VTRS, and MRNA

Should you buy Centessa Pharmaceuticals stock or one of its competitors? MarketBeat compares Centessa Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Centessa Pharmaceuticals include Insmed (INSM), BioNTech (BNTX), Roivant Sciences (ROIV), Viatris (VTRS), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does Centessa Pharmaceuticals compare to Insmed?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Centessa Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Centessa Pharmaceuticals currently has a consensus price target of $41.33, suggesting a potential upside of 3.72%. Insmed has a consensus price target of $210.95, suggesting a potential upside of 103.11%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

In the previous week, Insmed had 12 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 16 mentions for Insmed and 4 mentions for Centessa Pharmaceuticals. Insmed's average media sentiment score of 1.52 beat Centessa Pharmaceuticals' score of 1.33 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	14 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Centessa Pharmaceuticals has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Centessa Pharmaceuticals' return on equity of -60.37% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Insmed	-144.44%	-130.11%	-51.57%

Centessa Pharmaceuticals has higher earnings, but lower revenue than Insmed. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	396.45	-$197.53M	-$1.79	N/A
Insmed	$606.42M	37.12	-$1.28B	-$5.75	N/A

Summary

Centessa Pharmaceuticals beats Insmed on 9 of the 17 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

Centessa Pharmaceuticals has lower revenue, but higher earnings than BioNTech. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	6.89	-$1.29B	-$5.88	N/A
Centessa Pharmaceuticals	$15M	396.45	-$197.53M	-$1.79	N/A

In the previous week, BioNTech had 6 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 10 mentions for BioNTech and 4 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat BioNTech's score of 0.59 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Centessa Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Centessa Pharmaceuticals has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

15.5% of BioNTech shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioNTech currently has a consensus price target of $129.56, suggesting a potential upside of 46.48%. Centessa Pharmaceuticals has a consensus price target of $41.33, suggesting a potential upside of 3.72%. Given BioNTech's stronger consensus rating and higher possible upside, research analysts clearly believe BioNTech is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Summary

BioNTech beats Centessa Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Roivant Sciences?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Centessa Pharmaceuticals presently has a consensus target price of $41.33, suggesting a potential upside of 3.72%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential upside of 17.04%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Centessa Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	396.45	-$197.53M	-$1.79	N/A
Roivant Sciences	$8.26M	2,499.16	-$299.77M	-$0.60	N/A

In the previous week, Roivant Sciences had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 6 mentions for Roivant Sciences and 4 mentions for Centessa Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.42 beat Centessa Pharmaceuticals' score of 1.33 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Centessa Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Summary

Roivant Sciences beats Centessa Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, Centessa Pharmaceuticals had 3 more articles in the media than Viatris. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 1 mentions for Viatris. Viatris' average media sentiment score of 1.89 beat Centessa Pharmaceuticals' score of 1.33 indicating that Viatris is being referred to more favorably in the media.

Company	Overall Sentiment
Viatris	Very Positive
Centessa Pharmaceuticals	Positive

Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Centessa Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.27	-$3.51B	-$0.26	N/A
Centessa Pharmaceuticals	$15M	396.45	-$197.53M	-$1.79	N/A

79.9% of Viatris shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Viatris currently has a consensus target price of $16.43, indicating a potential upside of 5.58%. Centessa Pharmaceuticals has a consensus target price of $41.33, indicating a potential upside of 3.72%. Given Viatris' stronger consensus rating and higher probable upside, equities analysts plainly believe Viatris is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Summary

Centessa Pharmaceuticals beats Viatris on 8 of the 15 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Moderna?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Moderna	-143.55%	-26.64%	-19.32%

Centessa Pharmaceuticals presently has a consensus target price of $41.33, suggesting a potential upside of 3.72%. Moderna has a consensus target price of $35.73, suggesting a potential downside of 27.16%. Given Centessa Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Centessa Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Centessa Pharmaceuticals has higher earnings, but lower revenue than Moderna. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	396.45	-$197.53M	-$1.79	N/A
Moderna	$1.94B	10.01	-$2.82B	-$8.15	N/A

Centessa Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

In the previous week, Moderna had 24 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 28 mentions for Moderna and 4 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat Moderna's score of 0.46 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	10 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Neutral

Summary

Centessa Pharmaceuticals beats Moderna on 10 of the 16 factors compared between the two stocks.

Get Centessa Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTA vs. The Competition

Export

Metric	Centessa Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.95B	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-22.26	12.23	18.89	22.53
Price / Sales	396.45	302.27	520.79	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	10.17	3.85	9.84	6.72
Net Income	-$197.53M	$75.85M	$3.57B	$337.19M
7 Day Performance	0.20%	-1.67%	-1.16%	0.48%
1 Month Performance	0.71%	22.18%	3.85%	5.07%
1 Year Performance	198.28%	21.83%	27.40%	34.25%

Centessa Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTA Centessa Pharmaceuticals	2.1382 of 5 stars	$39.85 -0.1%	$41.33 +3.7%	+197.5%	$5.95B	$15M	N/A	200	Positive News
INSM Insmed	3.7586 of 5 stars	$108.87 +2.5%	$210.95 +93.8%	+44.7%	$23.60B	$606.42M	N/A	1,664	Positive News
BNTX BioNTech	3.6634 of 5 stars	$92.25 +0.1%	$128.44 +39.2%	-21.2%	$23.33B	$3.25B	N/A	7,807	Analyst Forecast
ROIV Roivant Sciences	2.8724 of 5 stars	$29.67 -1.0%	$33.59 +13.2%	+152.9%	$21.23B	$8.26M	N/A	860	Positive News
VTRS Viatris	3.227 of 5 stars	$16.26 -2.3%	$16.43 +1.0%	+80.6%	$18.94B	$14.30B	N/A	30,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTA) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Centessa Pharmaceuticals (CNTA) Competitors

CNTA vs. INSM, BNTX, ROIV, VTRS, and MRNA

How does Centessa Pharmaceuticals compare to Insmed?

Summary

How does Centessa Pharmaceuticals compare to BioNTech?

Summary

How does Centessa Pharmaceuticals compare to Roivant Sciences?

Summary

How does Centessa Pharmaceuticals compare to Viatris?

Summary

How does Centessa Pharmaceuticals compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTA vs. The Competition

Centessa Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Centessa Pharmaceuticals (CNTA) Competitors

CNTA vs. INSM, BNTX, ROIV, VTRS, and MRNA

How does Centessa Pharmaceuticals compare to Insmed?

Do institutionals & insiders hold more shares of CNTA or INSM?

Which has more volatility & risk, CNTA or INSM?

Do analysts recommend CNTA or INSM?

Does the media favor CNTA or INSM?

Is CNTA or INSM more profitable?

Which has preferable earnings & valuation, CNTA or INSM?

Summary

How does Centessa Pharmaceuticals compare to BioNTech?

Which has preferable valuation & earnings, BNTX or CNTA?

Does the media prefer BNTX or CNTA?

Which has more volatility and risk, BNTX or CNTA?

Is BNTX or CNTA more profitable?

Do institutionals and insiders hold more shares of BNTX or CNTA?

Do analysts recommend BNTX or CNTA?

Summary

How does Centessa Pharmaceuticals compare to Roivant Sciences?

Is CNTA or ROIV more profitable?

Do analysts recommend CNTA or ROIV?

Do institutionals & insiders hold more shares of CNTA or ROIV?

Which has preferable earnings & valuation, CNTA or ROIV?

Does the media refer more to CNTA or ROIV?

Which has more volatility & risk, CNTA or ROIV?

Summary

How does Centessa Pharmaceuticals compare to Viatris?

Does the media prefer VTRS or CNTA?

Which has more risk and volatility, VTRS or CNTA?

Which has higher earnings & valuation, VTRS or CNTA?

Do insiders and institutionals believe in VTRS or CNTA?

Is VTRS or CNTA more profitable?

Do analysts rate VTRS or CNTA?

Summary

How does Centessa Pharmaceuticals compare to Moderna?

Do insiders & institutionals hold more shares of CNTA or MRNA?

Is CNTA or MRNA more profitable?

Do analysts prefer CNTA or MRNA?

Which has stronger earnings and valuation, CNTA or MRNA?

Which has more volatility & risk, CNTA or MRNA?

Does the media favor CNTA or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTA vs. The Competition

Centessa Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools